Skip to main content

Advertisement

Log in

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

References

  1. Ferrara F, Schiffer CA . Acute myeloid leukaemia in adults. Lancet 2013; 381: 484–495.

    Article  Google Scholar 

  2. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015; 29: 312–320.

    Article  CAS  Google Scholar 

  3. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.

    Article  CAS  Google Scholar 

  4. Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012; 120: 2297–2306.

    Article  Google Scholar 

  5. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259.

    Article  CAS  Google Scholar 

  6. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423.

    Article  Google Scholar 

  7. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  Google Scholar 

  8. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2014; 32: 548–556.

    Article  Google Scholar 

  9. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086–2093.

    Article  CAS  Google Scholar 

  10. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090–1098.

    Article  CAS  Google Scholar 

  11. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172–4174.

    Article  CAS  Google Scholar 

  12. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009; 23: 350–357.

    Article  CAS  Google Scholar 

  13. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889–3897.

    Article  Google Scholar 

  14. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.

    Article  Google Scholar 

Download references

Acknowledgements

Research reported in this publication was supported by grants from the National Cancer Institute/National Institutes of Health (NCI/NIH; R21-CA182010 to RBW and MO, and R01-CA090998-09 to MO). The E1900 study was conducted by the ECOG-ACRIN Cancer Research Group (Robert L Comis, and Mitchell D Schnall, group co-chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA189859, CA180867, and CA180791 from the NCI/NIH and the Department of Health and Human Services. RBW is a Leukemia and Lymphoma Society Scholar in Clinical Research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R B Walter.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walter, R., Othus, M., Paietta, E. et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 29, 2104–2107 (2015). https://doi.org/10.1038/leu.2015.76

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.76

  • Springer Nature Limited

This article is cited by

Navigation